Guideline Recommendations for Community‑Acquired Pneumonia in Adults

Outpatient Management

Healthy Adults Without Comorbidities

Amoxicillin 1 g three times daily is the preferred first‑line therapy (strong recommendation, high‑quality evidence) according to the 2019 ATS/IDSA guidelines. 1
Doxycycline 100 mg twice daily is an alternative option (conditional recommendation). 2
Macrolide monotherapy (azithromycin or clarithromycin) may be used only when local pneumococcal macrolide resistance is < 25 %. 1

Adults With Comorbidities (e.g., diabetes, chronic organ disease, alcoholism, malignancy, asplenia)

Combination therapy with amoxicillin‑clavulanate plus a macrolide or doxycycline is preferred (strong recommendation). [1][2]
Respiratory fluoroquinolone monotherapy (levofloxacin, moxifloxacin, or gemifloxacin) is an acceptable alternative (strong recommendation). 1
Alternative β‑lactams for combination therapy include cefpodoxime or cefuroxime. 1

Inpatient Non‑ICU Management

β‑lactam (e.g., ampicillin‑sulbactam, cefotaxime, ceftriaxone, or ceftaroline) plus a macrolide is recommended (strong recommendation, high‑quality evidence). 2
Respiratory fluoroquinolone monotherapy (levofloxacin or moxifloxacin) is an equivalent option (strong recommendation, high‑quality evidence). 2
If both macrolides and fluoroquinolones are contraindicated, use a β‑lactam plus doxycycline. 2
Meta‑analyses show comparable clinical outcomes between β‑lactam/macrolide combination and fluoroquinolone monotherapy; fluoroquinolones have fewer treatment discontinuations, while combination therapy may confer a mortality benefit in observational studies. 2

Severe CAP Requiring ICU Admission

Combination therapy with a β‑lactam (e.g., cefotaxime, ceftriaxone, or ampicillin‑sulbactam) plus azithromycin is strongly recommended. 3
Alternatively, a β‑lactam plus a respiratory fluoroquinolone (levofloxacin or moxifloxacin) is acceptable. [2][3]
Observational data from ~10 000 critically ill patients indicate that macrolide‑containing regimens reduce mortality by 18 % relative risk (≈3 % absolute risk reduction) compared with non‑macrolide regimens. 2

Special Pathogen Coverage

When risk factors for Pseudomonas aeruginosa are present (e.g., structural lung disease, recent broad‑spectrum antibiotics, recent hospitalization), add an antipseudomonal β‑lactam (piperacillin‑tazobactam, cefepime, imipenem, or meropenem) plus either ciprofloxacin/levofloxacin or an aminoglycoside plus azithromycin or a fluoroquinolone. [3][4]5
When risk factors for MRSA are present (e.g., prior MRSA infection, intravenous drug use, recent influenza), add vancomycin or linezolid to the regimen. 3

Treatment Duration and Monitoring

A minimum of 5 days of therapy is sufficient if the patient has been afebrile for 48–72 hours and exhibits no more than one sign of clinical instability (e.g., tachycardia, tachypnea, hypotension, hypoxia, inability to maintain oral intake, altered mental status). [4][5]6
Extend therapy when the initial regimen was inactive against the identified pathogen or when extrapulmonary complications (e.g., meningitis, endocarditis) occur. 4
Switch from intravenous to oral antibiotics when the patient is hemodynamically stable, clinically improving, able to ingest medication, and has a functional gastrointestinal tract. [5][6]
Patients may be discharged immediately after the IV‑to‑oral switch without additional observation. 5

Critical Management Considerations

Administer the first dose of antibiotics in the emergency department before hospital admission to reduce mortality associated with treatment delay. [5][6]

Common Pitfalls to Avoid

Do not use macrolide monotherapy in regions where pneumococcal macrolide resistance exceeds 25 %. 1
Avoid fluoroquinolone first‑line therapy for healthy outpatients without comorbidities, due to resistance promotion and FDA warnings for serious adverse effects. 1
Do not add MRSA or Pseudomonas coverage without specific risk factors, as this leads to unnecessary broad‑spectrum exposure. 3
Do not continue antibiotics beyond 5 days in clinically stable patients, to prevent resistance and adverse events. 4
Do not delay ICU admission for patients meeting severe CAP criteria, as delays are linked to higher mortality. 1

Evidence‑Based Recommendations for Adult Community‑Acquired Pneumonia

Outpatient Management

Macrolide monotherapy (azithromycin or clarithromycin) should be used only when local pneumococcal macrolide resistance is < 25 %, because higher resistance rates diminish efficacy. ATS/IDSA guideline 7
For adults with comorbidities, the preferred regimen is amoxicillin‑clavulanate (2 g twice daily) combined with a macrolide or doxycycline, reflecting stronger coverage for higher‑risk patients. ATS/IDSA guideline 7
Respiratory fluoroquinolone monotherapy (e.g., levofloxacin 750 mg daily, moxifloxacin, or gemifloxacin) is an acceptable alternative for patients with comorbidities, supported by strong evidence. ATS/IDSA guideline 7
When amoxicillin‑clavulanate is unsuitable, alternative β‑lactams such as ceftriaxone, cefpodoxime, or cefuroxime (500 mg twice daily) can be used in combination therapy, providing comparable antimicrobial breadth. ATS/IDSA guideline 7

Inpatient Non‑ICU Management

A β‑lactam (ampicillin‑sulbactam, cefotaxime, ceftriaxone, or ceftaroline) plus a macrolide is the recommended regimen, with strong evidence showing improved clinical outcomes. ATS/IDSA guideline 8
Respiratory fluoroquinolone monotherapy (levofloxacin or moxifloxacin) is an equivalent alternative, achieving comparable outcomes in meta‑analyses. ATS/IDSA guideline 8
Preferred β‑lactam agents are cefotaxime, ceftriaxone, and ampicillin; ertapenem may be selected for patients at risk for gram‑negative pathogens (excluding Pseudomonas). ATS/IDSA guideline 8

Severe CAP Requiring ICU Admission

Combination therapy with a β‑lactam (ceftriaxone, cefotaxime, or ampicillin‑sulbactam) plus azithromycin is strongly recommended as the preferred ICU regimen. ATS/IDSA guideline 8
A β‑lactam plus a respiratory fluoroquinolone (levofloxacin 750 mg or moxifloxacin) is an acceptable alternative, backed by level I evidence. ATS/IDSA guideline 8

Special Pathogen Coverage in ICU Patients

For patients with risk factors for Pseudomonas aeruginosa, use an antipseudomonal β‑lactam (piperacillin‑tazobactam, cefepime, imipenem, or meropenem) together with either a fluoroquinolone (ciprofloxacin/levofloxacin 750 mg), an aminoglycoside + azithromycin, or an aminoglycoside + antipneumococcal fluoroquinolone. ATS/IDSA guideline 8
In penicillin‑allergic patients with Pseudomonas risk, substitute aztreonam for the β‑lactam. ATS/IDSA guideline 8
When MRSA risk factors are present (e.g., prior MRSA infection, IV drug use, recent influenza, known colonization), add vancomycin or linezolid to the empirical regimen. ATS/IDSA guideline 8

Treatment Duration, Monitoring, and IV‑to‑Oral Switch

Switch from intravenous to oral antibiotics once the patient is hemodynamically stable, clinically improving, able to take oral medication, and has a functional gastrointestinal tract—typically after 2–3 days of IV therapy. ATS/IDSA guideline 8

Critical Timing Considerations

Administer the first dose of antibiotics in the emergency department before hospital admission; delays are associated with increased mortality. ATS/IDSA guideline 8

Antimicrobial Stewardship and Common Pitfalls

Avoid macrolide monotherapy in regions where pneumococcal macrolide resistance exceeds 25 %, as efficacy is compromised. ATS/IDSA guideline 7
Reserve fluoroquinolones for patients with comorbidities or β‑lactam contraindications; do not use them as first‑line therapy for healthy outpatients, given safety warnings and resistance concerns. ATS/IDSA guideline 7
Do not add MRSA or Pseudomonas coverage without documented risk factors, to prevent unnecessary broad‑spectrum use and resistance. ATS/IDSA guideline 8
Avoid reusing an antimicrobial class that the patient received within the previous 3 months, thereby reducing the risk of resistance development. ATS/IDSA guideline 7

American Thoracic Society / IDSA Guidelines for Management of Community‑Acquired Pneumonia

Outpatient Management

Healthy Adults (no comorbidities)

Amoxicillin 1 g three times daily is the preferred first‑line regimen (strong recommendation, high‑quality evidence) – American Thoracic Society/IDSA 9
Doxycycline 100 mg twice daily is an acceptable alternative (conditional recommendation) – American Thoracic Society/IDSA 9
Macrolide monotherapy (azithromycin or clarithromycin) should be used only when local pneumococcal macrolide resistance is < 25 % (critical threshold) – American Thoracic Society/IDSA 9

Adults with Comorbidities or Recent Antibiotic Use

Amoxicillin‑clavulanate plus a macrolide or doxycycline is recommended (strong recommendation, Level I evidence) – American Thoracic Society/IDSA 9
Alternative β‑lactams for combination therapy include ceftriaxone, cefpodoxime, or cefuroxime (supported by clinical data) – American Thoracic Society/IDSA 10
Respiratory fluoroquinolone monotherapy (levofloxacin, moxifloxacin, or gemifloxacin) is an equivalent alternative (strong recommendation, Level I evidence) – American Thoracic Society/IDSA 9
Avoid reusing an antibiotic class received within the prior 3 months to limit resistance development (moderate recommendation) – American Thoracic Society/IDSA 10

Inpatient Non‑ICU Management

β‑lactam (ceftriaxone, cefotaxime, ampicillin‑sulbactam, or ceftaroline) plus a macrolide (preferably azithromycin) is the preferred regimen (strong recommendation, Level I evidence) – American Thoracic Society/IDSA 11
Respiratory fluoroquinolone monotherapy (levofloxacin or moxifloxacin) is an equivalent alternative (strong recommendation, Level I evidence) – American Thoracic Society/IDSA 11
Ertapenem may be selected for patients with risk factors for gram‑negative pathogens excluding Pseudomonas aeruginosa (moderate recommendation) – American Thoracic Society/IDSA 11

Severe CAP Requiring ICU Admission

Standard Regimens

β‑lactam (ceftriaxone, cefotaxime, or ampicillin‑sulbactam) plus azithromycin (strong recommendation, Level II evidence for azithromycin) – American Thoracic Society/IDSA 11
β‑lactam plus a respiratory fluoroquinolone is an acceptable alternative (strong recommendation, Level I evidence) – American Thoracic Society/IDSA 11

Antipseudomonal Coverage (when risk factors present)

Risk factors: structural lung disease, recent broad‑spectrum antibiotics, recent hospitalization with parenteral antibiotics (≤90 days), prior P. aeruginosa isolation – American Thoracic Society/IDSA 9
Regimen: antipseudomonal β‑lactam (piperacillin‑tazobactam, cefepime, imipenem, or meropenem) plus
- a fluoroquinolone (ciprofloxacin or levofloxacin 750 mg daily) or
- an aminoglycoside + azithromycin or
- an aminoglycoside + antipneumococcal fluoroquinolone (moderate recommendation, Level III evidence) – American Thoracic Society/IDSA 12
Penicillin‑allergic patients: substitute aztreonam for the β‑lactam component – American Thoracic Society/IDSA 12

MRSA Coverage (when risk factors present)

Risk factors: prior MRSA infection/colonization, intravenous drug use, recent influenza, known MRSA nasal colonization – American Thoracic Society/IDSA 9
Add vancomycin or linezolid to the empirical regimen (moderate recommendation, Level III evidence) – American Thoracic Society/IDSA 11

Antimicrobial Duration, Clinical Stability, and Switch

Minimum 5 days of therapy is sufficient if the patient has been afebrile for 48–72 h and exhibits ≤ 1 sign of clinical instability (moderate recommendation, Level I–II evidence) – American Thoracic Society/IDSA 11
Signs of clinical instability include tachycardia, tachypnea, hypotension, hypoxia, inability to maintain oral intake, or altered mental status – American Thoracic Society/IDSA 11
Extend therapy when the initial regimen was inactive against the identified pathogen or when extrapulmonary complications (e.g., meningitis, endocarditis) occur – American Thoracic Society/IDSA 11
IV‑to‑oral switch is appropriate when the patient is hemodynamically stable, clinically improving, able to ingest medications, and has a functional gastrointestinal tract (strong recommendation, Level II evidence) – American Thoracic Society/IDSA 11
Discharge can occur immediately after the IV‑to‑oral switch without additional inpatient observation (moderate recommendation, Level II evidence) – American Thoracic Society/IDSA 11

Timing of First Dose

Administer the first antibiotic dose in the emergency department before hospital admission; delays are associated with increased mortality (moderate recommendation, Level III evidence) – American Thoracic Society/IDSA 11

Diagnostic Testing

Outpatients: routine microbiological testing is not recommended – American Thoracic Society/IDSA 9
Hospitalized patients: obtain blood cultures and sputum Gram stain/culture (when a quality specimen is obtainable) in the presence of severe CAP, ICU admission, failure of outpatient therapy, cavitary infiltrates, leukopenia, active alcohol abuse, chronic severe liver disease, asplenia, pleural effusion, or positive urinary antigen tests (moderate recommendation, Level I‑II evidence) – American Thoracic Society/IDSA 10
Pneumococcal urinary antigen testing is suggested for severe CAP only (conditional recommendation, low‑quality evidence) – American Thoracic Society/IDSA 9
Legionella urinary antigen testing is suggested for severe CAP or when epidemiologic factors (outbreak, recent travel) are present (conditional recommendation, low‑quality evidence) – American Thoracic Society/IDSA 9
Intubated ICU patients: obtain an endotracheal aspirate for culture – American Thoracic Society/IDSA 10

Special Considerations: Pandemic Influenza (e.g., H5N1)

Suspected H5N1 infection: treat with oseltamivir plus antibacterial agents active against Streptococcus pneumoniae and Staphylococcus aureus (moderate recommendation, Level II‑III evidence) – American Thoracic Society/IDSA 11
Infection‑control: use droplet precautions and maintain isolation until H5N1 is ruled out (moderate recommendation, Level III evidence) – American Thoracic Society/IDSA 11

Critical Pitfalls (Key Safety Points)

Do not use macrolide monotherapy when local pneumococcal macrolide resistance exceeds 25 %; efficacy is markedly reduced – American Thoracic Society/IDSA 9
Reserve fluoroquinolones for patients with comorbidities or β‑lactam contraindications; avoid first‑line use in healthy outpatients due to safety warnings and resistance concerns – (guideline consensus)
Avoid adding MRSA or Pseudomonas coverage without documented risk factors to prevent unnecessary broad‑spectrum exposure and resistance – (guideline consensus)

Empiric Therapy, Treatment Duration, and Management Milestones for Adult Community‑Acquired Pneumonia (Cited Evidence)

Coverage for Special Pathogens

Pseudomonas‑risk patients – Use an antipseudomonal β‑lactam (piperacillin‑tazobactam, cefepime, imipenem, or meropenem) plus either a high‑dose fluoroquinolone (ciprofloxacin or levofloxacin) or an aminoglycoside combined with azithromycin or a pneumococcal‑active fluoroquinolone. 13
Penicillin‑allergic patients with Pseudomonas risk – Substitute aztreonam for the β‑lactam component while retaining the remainder of the regimen. 13
MRSA‑risk patients – Add vancomycin or linezolid to the empiric antibiotic regimen when any MRSA risk factor is present (prior MRSA infection/colonization, IV drug use, recent influenza, known nasal colonization). 13

Minimum Treatment Duration and Monitoring

Minimum five‑day course – A total of ≥ 5 days of therapy is sufficient if the patient has been afebrile for 48–72 h and shows ≤ 1 sign of clinical instability (e.g., tachycardia, tachypnea, hypotension, hypoxia, inability to maintain oral intake, altered mental status). 13
Extension criteria – Prolong therapy beyond five days only when the initial regimen failed to cover the identified pathogen or when extrapulmonary complications (e.g., meningitis, endocarditis) arise. 13

Transition from Intravenous to Oral Therapy

Switch criteria – Convert to oral antibiotics once the patient is hemodynamically stable, clinically improving, able to ingest medication, and has a functional gastrointestinal tract; this transition typically occurs after 2–3 days of IV therapy. 13
Discharge after switch – Patients may be discharged immediately after the IV‑to‑oral change without additional inpatient observation. 13

Timing of Initial Antibiotic Administration

First‑dose timing – Administer the first antibiotic dose in the emergency department before hospital admission; delays are associated with higher mortality. 13

Avoidance of Unnecessary Prolongation

Do not exceed five days – In clinically stable patients, continue antibiotics no longer than five days to limit resistance development and adverse events. 13

Community‑Acquired Pneumonia – Evidence‑Based Diagnostic and Therapeutic Recommendations

Diagnostic Testing Strategy

Outpatient CAP does not require routine microbiological testing because the yield is low and results rarely alter management (Infectious Diseases Society of America [IDSA] guideline) 14.
In hospitalized patients, blood cultures and sputum Gram‑stain/culture should be obtained only when high‑risk features are present (e.g., severe disease requiring ICU, failure of outpatient therapy, cavitary infiltrates, leukopenia, alcohol abuse, severe liver disease, asplenia, pleural effusion needing drainage, or positive pneumococcal/Legionella urinary antigens) 14.
All ICU patients must have blood cultures, pneumococcal and Legionella urinary antigen tests, and sputum (or endotracheal aspirate if intubated) collected for culture (IDSA) 14, 15.
Sputum specimens are considered adequate only when they contain < 10 squamous epithelial cells and > 25 neutrophils per low‑power field 14.

Outpatient Empirical Antibiotic Therapy

Previously Healthy Adults (No Comorbidities)

Amoxicillin 1 g three times daily is the preferred first‑line regimen (shift from macrolide‑first due to rising macrolide resistance) 14.
Doxycycline 100 mg twice daily is an acceptable alternative when amoxicillin is contraindicated 14.
Macrolide monotherapy (azithromycin or clarithromycin) should be used only if local pneumococcal macrolide resistance is < 25 %; otherwise it is not recommended 14.

Adults With Comorbidities or Risk Factors for Drug‑Resistant Streptococcus pneumoniae

Risk‑factor list includes chronic heart, lung, liver, or renal disease; diabetes; alcoholism; malignancy; asplenia; immunosuppression; or recent antibiotic use (≤ 3 months) 14, 15.
Two equivalent regimens are recommended:
- Amoxicillin‑clavulanate 2 g twice daily plus a macrolide (azithromycin/clarithromycin) or doxycycline; alternative β‑lactams (ceftriaxone, cefpodoxime, cefuroxime) are acceptable 14, 15.
- Respiratory fluoroquinolone monotherapy (levofloxacin 750 mg daily, moxifloxacin, or gemifloxacin) 14.
Avoid reusing any antibiotic class received within the prior 3 months, as this markedly increases resistance risk 14.

Inpatient Non‑ICU Empirical Therapy

Two regimens have equivalent efficacy according to meta‑analyses:
- β‑lactam (ceftriaxone, cefotaxime, ampicillin‑sulbactam, or ceftaroline) plus a macrolide (preferably azithromycin) – may confer a mortality benefit in observational studies 16.
- Respiratory fluoroquinolone monotherapy (levofloxacin 750 mg daily or moxifloxacin) – associated with fewer treatment discontinuations but lacks the potential immunomodulatory effect of macrolides 16.
Ertapenem can be selected for patients with risk factors for gram‑negative pathogens (excluding Pseudomonas), such as aspiration risk or nursing‑home residence 16.
Penicillin‑allergic patients should receive a respiratory fluoroquinolone 16.

Severe CAP Requiring ICU Admission

Combination therapy is mandatory; the preferred regimen is a β‑lactam (ceftriaxone, cefotaxime, or ampicillin‑sulbactam) plus azithromycin (IDSA) 16.
Observational data from ~10 000 critically ill patients show that macrolide‑containing regimens reduce mortality by 18 % relative risk (≈ 3 % absolute risk reduction) 16.
Alternative ICU regimen: β‑lactam plus a respiratory fluoroquinolone (levofloxacin 750 mg or moxifloxacin) 16.

Antipseudomonal Coverage (When Specific Risk Factors Exist)

Risk factors: structural lung disease (e.g., bronchiectasis, frequent COPD exacerbations), recent broad‑spectrum antibiotics, recent hospitalization with parenteral antibiotics (≤ 90 days), or prior Pseudomonas isolation 16.
Regimen options:
- Antipseudomonal β‑lactam (piperacillin‑tazobactam, cefepime, imipenem, or meropenem) + ciprofloxacin or levofloxacin 750 mg;
- Antipseudomonal β‑lactam + aminoglycoside (gentamicin or tobramycin) + azithromycin;
- Antipseudomonal β‑lactam + aminoglycoside + antipneumococcal fluoroquinolone.
For penicillin‑allergic patients, substitute aztreonam for the β‑lactam 16.

MRSA Coverage (When Specific Risk Factors Exist)

Risk factors: prior MRSA infection/colonization, intravenous drug use, recent influenza outbreak, or known MRSA nasal colonization 16.
Add vancomycin or linezolid to the empirical regimen; do not add MRSA coverage without documented risk factors 16.

Treatment Duration and Clinical Stability

A minimum of 5 days of therapy is sufficient if the patient has been afebrile for 48–72 h and exhibits ≤ 1 sign of clinical instability (e.g., heart rate > 100 bpm, respiratory rate > 24/min, systolic BP < 90 mmHg, SpO₂ < 90 % on room air, inability to maintain oral intake, altered mental status) 16.
Extend therapy beyond 5 days only when the initial regimen was inactive against the identified pathogen or when extrapulmonary complications (meningitis, endocarditis, empyema) develop 16.

IV‑to‑Oral Switch and Discharge

Switch to oral antibiotics when the patient is hemodynamically stable, clinically improving, able to ingest medication, and has a functional gastrointestinal tract—typically after 2–3 days of IV therapy 16.
Patients may be discharged immediately after the IV‑to‑oral switch without additional inpatient observation 16.

Timing of First Antibiotic Dose

The first antibiotic dose should be administered in the emergency department before hospital admission; delays are associated with increased mortality, especially in severe CAP 16.

Special Considerations: Pandemic Influenza (e.g., H5N1)

For suspected H5N1 infection, treat with oseltamivir plus antibacterial agents targeting Streptococcus pneumoniae and Staphylococcus aureus; employ droplet precautions and maintain isolation until H5N1 is ruled out 16.

Key Pitfalls (Cited)

Do not use macrolide monotherapy when local pneumococcal macrolide resistance exceeds 25 %, as efficacy is markedly reduced 14.
Do not obtain sputum cultures unless quality standards are met (< 10 squamous epithelial cells per low‑power field), because poor‑quality specimens yield misleading results 14.

Antibiotic and Glucocorticoid Management of Community‑Acquired Pneumonia in Adults with Interstitial Lung Disease on Chronic Steroids

Antibiotic Selection

Non‑Severe CAP (ward admission)

Preferred regimen: a β‑lactam (e.g., ceftriaxone, cefotaxime, or ampicillin‑sulbactam) combined with a macrolide (azithromycin or clarithromycin). Strong recommendation based on guideline consensus. 17
Alternative regimen: respiratory fluoroquinolone monotherapy (levofloxacin 750 mg daily or moxifloxacin) provides outcomes comparable to β‑lactam + macrolide in meta‑analyses. Equivalent efficacy demonstrated. 17
Timing of first dose: administer the initial antibiotic dose in the emergency department before hospital admission; delays are associated with increased mortality. Observational evidence. [18][17]

Severe CAP (ICU admission)

Strongly recommended regimen: a β‑lactam (ceftriaxone, cefotaxime, or ampicillin‑sulbactam) plus azithromycin. Strong recommendation for ICU patients. 17
Alternative regimen: a β‑lactam combined with a respiratory fluoroquinolone (levofloxacin 750 mg or moxifloxacin). Acceptable alternative with similar outcomes. 17

Coverage for Special Pathogens

Antipseudomonal coverage (piperacillin‑tazobactam, cefepime, imipenem, or meropenem) plus ciprofloxacin or levofloxacin 750 mg should be added when the patient has structural lung disease, recent broad‑spectrum antibiotic exposure, or recent hospitalization with parenteral antibiotics within the past 90 days. Guideline‑based recommendation. 17
MRSA coverage (vancomycin or linezolid) is indicated only if MRSA risk factors are present (e.g., prior MRSA infection, intravenous drug use, recent influenza). Targeted therapy recommendation. 17

Glucocorticoid Management

Baseline Chronic Glucocorticoid Continuation

Do not increase or add supplemental corticosteroids for non‑severe CAP. The 2019 ATS/IDSA guidelines recommend against routine corticosteroid use in non‑severe CAP. Conditional recommendation against routine use. 19

Severe CAP Considerations

Routine corticosteroid supplementation beyond the patient’s baseline dose remains conditionally discouraged in severe CAP. Conditional recommendation. 19

Adrenal Insufficiency Screening

Screen for occult adrenal insufficiency only if refractory hypotension persists despite adequate fluid resuscitation and vasopressor support. Evidence‑based trigger for testing. [18][20]
If adrenal insufficiency is suspected, administer hydrocortisone 50 mg IV every 6 hours (or 200 mg/day continuous infusion) until hemodynamic stability is achieved. Therapeutic protocol. [18][20]

Treatment Duration and Monitoring

Minimum treatment duration: at least 5 days provided the patient has been afebrile for 48–72 hours and exhibits ≤1 sign of clinical instability (e.g., tachycardia, tachypnea, low systolic BP, low SpO₂, inability to maintain oral intake, altered mental status). Evidence‑based minimum duration. [18][17]
Extension of therapy: continue beyond 5 days only if the initial regimen was inactive against the identified pathogen or if extrapulmonary complications (meningitis, endocarditis, empyema) develop. Guideline‑driven extension criteria. [18][17]
Switch from IV to oral antibiotics when the patient is hemodynamically stable, clinically improving, able to ingest medication, and has a functional gastrointestinal tract—typically after 2–3 days of IV therapy. Transition recommendation. [18][17]

Critical Pitfalls to Avoid

Avoid empiric increase of glucocorticoid dose “for stress coverage” without documented adrenal insufficiency. Such practice raises the risk of hyperglycemia (relative risk 1.32) and may worsen infection outcomes in immunosuppressed patients. Safety warning. 19
Do not add MRSA or Pseudomonas coverage without documented risk factors. Unnecessary broad‑spectrum antibiotics promote antimicrobial resistance. Antibiotic stewardship principle. 17
Do not continue antibiotics beyond 5 days in clinically stable patients. Prolonged therapy increases adverse events without added benefit. Evidence‑based duration limit. [18][17]
Do not delay ICU transfer for patients meeting severe CAP criteria (need for vasopressors or mechanical ventilation). Delays are linked to higher mortality. Critical care timing recommendation. 17

Oral Step‑Down Therapy for High‑Risk Community‑Acquired Pneumonia Patients

Indication for Switching to Oral β‑lactams

In patients with multiple comorbidities (e.g., coronary artery disease, chronic heart failure, diabetes mellitus, chronic kidney disease, smoking, and alcohol use) who are classified as high‑risk and receive broad‑spectrum IV therapy (ceftriaxone + azithromycin), a transition to oral amoxicillin or amoxicillin‑clavulanate is appropriate once clinical stability is achieved, providing adequate antimicrobial coverage. 21

Antibiotic Recommendations for Adult Community‑Acquired Pneumonia

Outpatient Management – Previously Healthy Adults

First‑line therapy is amoxicillin 1 g orally three times daily (strong recommendation, high‑quality evidence) 22.
If amoxicillin is contraindicated, doxycycline 100 mg orally twice daily is an acceptable alternative (strong recommendation) 22.
Macrolide monotherapy (azithromycin or clarithromycin) should be used only when local pneumococcal macrolide resistance is < 25 %; efficacy falls markedly above this threshold (strong recommendation) 22.

Outpatient Management – Adults with Comorbidities or Recent Antibiotic Exposure

Two equivalent regimens are recommended:
Avoid re‑using any antibiotic class received in the preceding ≤ 3 months, as this markedly raises the risk of resistance (strong recommendation) 22.

Hospitalized (Non‑ICU) Management

Preferred regimen: a β‑lactam (ceftriaxone, cefotaxime, ampicillin‑sulbactam, or ceftaroline) plus a macrolide (preferably azithromycin) (strong recommendation, evidence level I) 23.
Alternative regimen: respiratory fluoroquinolone monotherapy (levofloxacin 750 mg daily or moxifloxacin) (strong recommendation, evidence level I) 23.
Observational data suggest that adding a macrolide may confer a mortality benefit in hospitalized patients (moderate evidence) 23.
For patients with risk factors for gram‑negative organisms (e.g., aspiration risk or residence in a long‑term care facility), ertapenem can be selected (moderate recommendation) 23.
Penicillin‑allergic patients should receive a respiratory fluoroquinolone (strong recommendation) 23.

ICU (Severe CAP) Management

Mandatory combined therapy: a β‑lactam (ceftriaxone, cefotaxime, or ampicillin‑sulbactam) plus azithromycin (strong recommendation, evidence level II) 23.
Observational cohort of ≈10 000 critically ill patients showed macrolide‑containing regimens reduced mortality by 18 % relative risk (≈3 % absolute risk reduction) (moderate evidence) 23.
Alternative combined regimen: β‑lactam plus a respiratory fluoroquinolone (levofloxacin 750 mg daily or moxifloxacin) (strong recommendation) 23.
When risk factors for Pseudomonas are present, any of the following antipseudomonal strategies are acceptable:
For patients allergic to penicillins, replace the β‑lactam component with aztreonam (strong recommendation) 23.
If MRSA risk factors exist (prior MRSA infection/colonization, IV drug use, recent influenza outbreak, or known nasal MRSA colonization), add vancomycin or linezolid to the empirical regimen (moderate recommendation, evidence level III) 23.

Duration of Therapy and Clinical Stability

A minimum of 5 days of antibiotics is sufficient provided the patient has been afebrile for 48–72 h and exhibits ≤ 1 sign of clinical instability (e.g., heart rate > 100 bpm, respiratory rate > 24/min, systolic BP < 90 mmHg, SpO₂ < 90 % on room air, inability to take oral intake, or altered mental status) (strong recommendation) 23.
Extend therapy beyond 5 days only if the initial regimen was inactive against the identified pathogen or if extrapulmonary complications (meningitis, endocarditis, empyema) develop (strong recommendation) 23.

Transition to Oral Therapy and Discharge

Switch to oral antibiotics when the patient is hemodynamically stable, clinically improving, able to ingest medication, and has a functional gastrointestinal tract—typically after 2–3 days of IV therapy (strong recommendation) 23.
Patients may be discharged immediately after the IV‑to‑oral switch without additional inpatient observation (moderate recommendation) 23.

Timing of the First Antibiotic Dose

The first dose should be administered in the emergency department before hospital admission; delays are associated with increased mortality, especially in severe CAP (strong recommendation) 23.

All facts are derived from peer‑reviewed sources (Clinical Infectious Diseases, 2003; Clinical Microbiology and Infection, 2011) and reflect the strength of evidence indicated in the original citations.

Guideline Recommendations for Aspiration and Community‑Acquired Pneumonia

Definition and Microbiology

Community‑acquired aspiration pneumonia should be managed with standard CAP regimens because the predominant pathogens are aerobic bacteria and mixed flora, not pure anaerobes, and these regimens already provide coverage for oral anaerobes. 24

Non‑Severe Community‑Acquired Aspiration Pneumonia (Ward Admission, No MDR Risk)

Use standard inpatient CAP therapy: a β‑lactam (e.g., ampicillin‑sulbactam 1.5–3 g IV q6 h, ceftriaxone 1–2 g IV daily, or cefotaxime 1–2 g IV q8 h) plus azithromycin 500 mg IV/PO daily (strong recommendation). 24
If a macrolide‑based combination is not feasible, a respiratory fluoroquinolone monotherapy (levofloxacin 750 mg IV/PO daily or moxifloxacin 400 mg IV/PO daily) is an acceptable alternative (strong recommendation). 24
Ampicillin‑sulbactam is especially appropriate because it combines β‑lactam activity with inherent anaerobic coverage, although other β‑lactams in combination regimens are equally effective. (strong recommendation) 24

Severe Community‑Acquired Aspiration Pneumonia (ICU Admission, Septic Shock, or Mechanical Ventilation)

Mandatory combination therapy: a β‑lactam (ceftriaxone, cefotaxime, or ampicillin‑sulbactam) plus azithromycin (strong recommendation). 24
An alternative regimen is a β‑lactam plus a respiratory fluoroquinolone (levofloxacin 750 mg or moxifloxacin) (strong recommendation). [24][25]
Add MRSA coverage (vancomycin 15 mg/kg IV q12 h or linezolid 600 mg IV q12 h) when any of the following risk factors are present: prior MRSA colonisation/infection, intravenous drug use, recent influenza, or known nasal MRSA colonisation. (strong recommendation) 24
Add antipseudomonal coverage (piperacillin‑tazobactam 4.5 g IV q6 h, cefepime 2 g IV q8 h, or meropenem 1 g IV q8 h) plus ciprofloxacin 400 mg IV q8 h or levofloxacin 750 mg IV daily when risk factors such as structural lung disease, recent broad‑spectrum antibiotics, recent hospitalization with IV antibiotics (≤90 days), or prior Pseudomonas isolation are identified. (strong recommendation) [24][25]

Healthcare‑Associated Aspiration Pneumonia (HCAAP)

Without severe illness or MDR risk factors: treat as standard inpatient CAP with a β‑lactam + macrolide or a respiratory fluoroquinolone monotherapy. (strong recommendation) 24
With ≥ 1 MDR risk factor (e.g., long‑term care residence, recent hospitalization, recent antibiotics, immunosuppression): broaden therapy to include MRSA and Pseudomonas coverage using an antipseudomonal β‑lactam plus a fluoroquinolone (ciprofloxacin or levofloxacin) plus vancomycin or linezolid. (strong recommendation) 24
If septic shock, ICU admission, or mechanical ventilation is required: add double Pseudomonas coverage (antipseudomonal β‑lactam + aminoglycoside + azithromycin + vancomycin or linezolid). (strong recommendation) 24

Standard Community‑Acquired Pneumonia (CAP) – Outpatient Treatment

Healthy adults (no comorbidities): amoxicillin 1 g PO three times daily (strong recommendation, first‑line). 24
Macrolide monotherapy (azithromycin or clarithromycin) is acceptable only when local pneumococcal macrolide resistance is < 25 %. (strong recommendation) 24
Adults with comorbidities (e.g., diabetes, chronic organ disease, alcoholism, malignancy, asplenia, immunosuppression, or recent antibiotics): amoxicillin‑clavulanate 2 g PO twice daily plus azithromycin or doxycycline (strong recommendation). 25
Alternative for comorbid patients: a respiratory fluoroquinolone monotherapy (levofloxacin 750 mg, moxifloxacin, or gemifloxacin) (strong recommendation). 25

Standard CAP – Inpatient Treatment

Non‑ICU ward patients: a β‑lactam (ceftriaxone, cefotaxime, ampicillin‑sulbactam, or ceftaroline) plus azithromycin (strong recommendation). 24
Alternative for non‑ICU patients: respiratory fluoroquinolone monotherapy (levofloxacin 750 mg or moxifloxacin) (strong recommendation). 24
Severe CAP (ICU admission): β‑lactam (ceftriaxone, cefotaxime, or ampicillin‑sulbactam) plus azithromycin reduces mortality by ~18 % relative risk compared with regimens lacking a macrolide (strong recommendation). 24
Alternative for severe CAP: β‑lactam plus a respiratory fluoroquinolone (strong recommendation). [24][25]

Duration of Therapy and Monitoring (Applicable to Both Aspiration and Standard CAP)

Minimum 5 days of antibiotics is adequate if the patient has been afebrile for 48–72 h and exhibits ≤ 1 sign of clinical instability (tachycardia > 100 bpm, tachypnea > 24/min, systolic BP < 90 mmHg, SpO₂ < 90 % on room air, inability to maintain oral intake, or altered mental status). (strong recommendation) 24
Extend therapy beyond 5 days only when the initial regimen is inactive against the identified pathogen or when extrapulmonary complications (e.g., meningitis, endocarditis, empyema) develop. (strong recommendation) 24
Switch from IV to oral antibiotics once the patient is hemodynamically stable, clinically improving, able to ingest medication, and has a functional gastrointestinal tract—typically after 2–3 days of IV therapy. (strong recommendation) 24
Patients may be discharged immediately after the IV‑to‑oral switch without additional inpatient observation. (strong recommendation) 24

Timing and Diagnostic Considerations

The first dose of antibiotics should be administered in the emergency department before hospital admission; delays are linked to increased mortality, especially in severe CAP. (strong recommendation) 24
Obtain blood cultures, sputum Gram stain/culture, and pneumococcal/Legionella urinary antigens only in severe CAP, ICU admission, outpatient treatment failure, cavitary infiltrates, leukopenia, active alcohol abuse, severe liver disease, asplenia, or pleural effusion. (strong recommendation) 24
Routine microbiological testing is not recommended for outpatient CAP. (strong recommendation) 24

Common Pitfalls to Avoid

Do not add routine anaerobic agents (e.g., metronidazole or clindamycin) to standard CAP regimens for aspiration pneumonia; β‑lactams in combination therapy already cover oral anaerobes. (strong recommendation) 24
Do not add MRSA or Pseudomonas coverage without documented risk factors, as this promotes unnecessary broad‑spectrum exposure and resistance. (strong recommendation) 24
Do not continue antibiotics beyond 5 days in clinically stable patients; prolonged therapy increases adverse events without added benefit. (strong recommendation) 24
Do not use macrolide monotherapy when local pneumococcal macrolide resistance exceeds 25 %; efficacy is markedly reduced. (strong recommendation) 24
Do not delay ICU transfer for patients meeting severe CAP criteria (need for vasopressors or mechanical ventilation); delays are associated with higher mortality. (strong recommendation) 24